Skip to content
Biotechnology

Cambridge Isotope Laboratories Launches ISOLED-D: Revolutionary Deuterated Reagents for OLED Manufacturing

Cambridge Isotope Laboratories, Inc. 2 mins read

New ISOLED-D™ line delivers premium, scalable deuterated reagents for OLED synthesis, supporting the industry from R&D through commercial production with CIL's global manufacturing and expertise.

TEWKSBURY, MASSACHUSETTS / ACCESS Newswire / May 20, 2025 / Cambridge Isotope Laboratories, Inc. (CIL), the global leader in stable isotope-labeled products, announces the launch of ISOLED-D™, a groundbreaking line of deuterated reagents specifically designed for organic light-emitting diode (OLED) synthesis.

ISOLED-D LOGO
ISOLED-D LOGO
ISOLED-D - deuterated reagents specifically designed for organic light-emitting diode

ISOLED-D represents a significant advancement in OLED manufacturing technology, offering high-quality deuterated reagents with manufacturing in state-of-the-art, strategically located worldwide facilities. The product line caters to various production scales, from gram quantities for research and development to metric-ton volumes for full-scale commercial manufacturing.

"ISOLED-D demonstrates our commitment to advancing OLED technology through innovative isotope-labeled solutions," said Tasha Agreste, Business Development Manager for Deuterated Reagents at CIL. "Our ability to scale production from laboratory to industrial quantities positions us as a crucial partner in the OLED manufacturing ecosystem."

The company's flexible approach enables seamless collaboration with research and development teams through to commercial production, ensuring consistent quality and reliable supply chains for manufacturers in the rapidly growing OLED market.

Key features of ISOLED-D:

  • Premium-grade deuterated reagents for OLED synthesis

  • Scalable production capabilities from grams to metric tons

  • Manufacturing in state-of-the-art facilities

  • Complete R&D to commercialization support

  • Backed by CIL's industry-leading expertise in stable isotope-labeled products

  • Deuterated Benzene Recovery program

For more information about ISOLED-D and CIL's complete range of isotope-labeled products, visit isotope.com.

Contact Information

Crissy Krisko
[email protected]
1.978.269.1930

.

SOURCE: Cambridge Isotope Laboratories, Inc.



View the original press release on ACCESS Newswire

More from this category

  • Biotechnology
  • 12/12/2025
  • 11:40
4DMedical Limited (ASX:4DX)

4DMedical secures $30.2 million with options underwrite

Highlights• $30.2 million in funding secured by entering into an underwriting agreement that ensures the exercise of all the 4DXO listed options• Additional funding results in a proforma cash balance as at 30 September 2025 of $63.7 million • 4DMedical is experiencing unprecedented interest in CT:VQ™, with multiple contract discussions underway, positioning CY26 as a transformational year Melbourne, Australia, 12 December 2025: 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”) today announces it has entered into an option underwriting agreement (Underwriting Agreement) with Bell Potter Securities Limited (Underwriter) to fully underwrite the exercise of the 4DXO listed options on issue,…

  • Biotechnology
  • 12/12/2025
  • 10:58
EBR Systems, Inc. (ASX:EBR)

First implant in the Totally Leadless CRT (TLC-AU) Study

Key Highlights • First patient enrolment and implant in the Totally Leadless CRT (TLC-AU) study by Dr Paul Gould from the Princess Alexandra Hospital, Brisbane • TLC-AU is a feasibility study into using the WiSE® System alongside a leadless pacemaker to achieve totally leadless CRT • The study represents a significant strategic milestone as EBR evaluates WiSE as a potential first-line therapy for treating newly diagnosed heart failure patients • TLC-AU could meaningfully expand EBR’s addressable market Sunnyvale, California; 12 December 2025: EBR Systems, Inc., developer of the world’s only wireless cardiac pacing device for heart failure, announces the first…

  • Biotechnology
  • 10/12/2025
  • 10:19
OncoSil Medical Limited (ASX:OSL)

First OncoSil treatment in United Kingdom

Sydney, Australia – 10 December 2025: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce the first commercial patient treatment in the UK using the OncoSil™ device. The successful treatment was performed on 9 December 2025 at Southampton General Hospital (University Hospital SouthamptonNHS Foundation Trust), a recognised centre of excellence in oncology. Following the hospital’s participation in the TRIPP-FFX clinical study, this significant milestone marks the transition from clinical trial involvement to the commencement of OncoSil’s commercial operations…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.